Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s):  SZLSF

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.


TSX:SZLS - Post by User

Post by InvrsContrarianon Mar 23, 2021 3:34pm
263 Views
Post# 32859871

Income trajectory

Income trajectory From that video he stated that the income trajectory is ongoig. Q1 11k Q2 99k Q3 1400k So 9x,14x. So from his perspective then Q4 will blow us away. A projection of 5x would give 7 million. But in all reality with a doubling of the the staffing we are looking at 2800k with additional monies from cash accrual from Q3 of around 20% of income for Q3 which was stated in another video. With that latest pp at 7 million, stagezero has a major windfall in cash presently and in the future with the covid revenue earmarked for promotion of Aristotle. Moneymarrket says news doesn't matter when looking at charts, but I'd say the chicken comes before the egg. The news makes the market and the market will want to buy stagezero stock. So do we jab the jugular first or sweep the leg of the market?
<< Previous
Bullboard Posts
Next >>